Pharmaceuticals

EAST-ASIA PHARMACEUTICAL

EAST-ASIA PHARMACEUTICAL released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 264.57 M, actual EPS CNY -0.31

EAST-ASIA PHARMACEUTICAL to Release FY2026 Q1 Earnings Report on April 30 After-Market BJT

EAST-ASIA PHARMACEUTICAL released FY2025 earnings on April 22 Pre-Market (BJT), actual revenue CNY 940.19 M (forecast CNY 2.244 B), actual EPS CNY -0.72 (forecast CNY 2.21)

EAST-ASIA PHARMACEUTICAL released FY2025 Q4 earnings on April 22 Pre-Market (BJT), actual revenue CNY 343.85 M, actual EPS CNY -0.0883

EAST-ASIA PHARMACEUTICAL to Release FY2025 Earnings on April 23, Pre-Market BJT; Forecast Revenue CNY 2.244 B, EPS CNY 2.21

EAST-ASIA PHARMACEUTICAL released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 180.48 M, actual EPS CNY -0.3756

EAST-ASIA PHARMACEUTICAL released FY2025 9 Months Earnings on October 30 Pre-Market BJT, actual revenue CNY 596.34 M, actual EPS CNY -0.6345

EAST-ASIA PHARMACEUTICAL to Release FY2025 Q3 Earnings on October 31 Pre-Market BJT

EAST-ASIA PHARMACEUTICAL released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue CNY 415.86 M, actual EPS CNY -0.26

EAST-ASIA PHARMACEUTICAL released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue CNY 224.94 M, actual EPS CNY -0.1988

EAST-ASIA PHARMACEUTICAL to Release FY2025 Semi-Annual Earnings on August 29, 2025 (BJT)

East Asia Pharmaceutical Expected to Report Non-GAAP Net Loss in First Half of 2025

East Asia Pharmaceutical's Subsidiary Obtains National Accreditation Committee Laboratory Accreditation

East Asia Pharmaceutical Obtained Registration Certificate for Levofloxacin Tablets

East Asia Pharmaceutical Reveals Reasons for 2024 Decline and Improvement Measures

East Asia Pharmaceutical Obtains Certificate for Trimedoxib API in South Korea

EAST Asia Pharmaceutical Reports Q1 Revenue Down 45.85%, Net Loss of 691.96 Million Yuan

EAST-ASIA PHARMACEUTICAL released FY2024 earnings on April 29 After-Market (BJT), actual revenue CNY 1.198 B (forecast CNY 1.634 B), actual EPS CNY -0.9 (forecast CNY 1.67)

EAST-ASIA PHARMACEUTICAL released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 190.92 M, actual EPS CNY -0.06

EAST-ASIA PHARMACEUTICAL released FY2024 Q4 earnings on April 29 After-Market (BJT), actual revenue CNY 235.22 M, actual EPS CNY -1.3426

605177

According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL disclosed its third-quarter report for 2025. The company achieved a revenue of 596 million yuan in the first three quarters, a year-on-year decrease of 38.08%; the net profit attributable to shareholders was a loss of 72.41 million yuan; the net profit excluding non-recurring items was a loss of 81.98 million yuan; the basic earnings per share were -0.63 yuan

Zhitong

EAST-ASIA PHARMACEUTICAL released its performance for the first three quarters, with a net loss attributable to the parent company of 72.41 million yuan

The Shanghai Stock Exchange issued a regulatory warning to Zhejiang East-Asia Pharmaceutical and related responsible persons due to discrepancies between the use of some raised funds and the initial public offering prospectus, failure to timely fulfill review procedures, and inaccurate information disclosure regarding the storage and actual use of raised funds. These actions violate relevant regulations

Wallstreetcn

The Shanghai Stock Exchange issued regulatory warnings to EAST-ASIA PHARMACEUTICAL and relevant responsible persons

601975

002609

603662

On August 25th, 4 companies announced their stock repurchase progress, among which 1 company disclosed its repurchase plan for the first time, and 3 companies have completed their repurchases. NJTC plans to repurchase no more than 400 million yuan. The completed repurchase amounts for JSST, Keli, and EAST-ASIA PHARMACEUTICAL are 9.3214 million yuan, 5.4361 million yuan, and 1.326 million yuan, respectively. So far this year, a total of 1,407 repurchase plans have been implemented, involving 1,105 companies, with 255 companies having repurchase amounts exceeding 100 million yuan. China COSCO Shipping, Tongwei Co., Ltd., and Jiuan Medical have the highest repurchase amounts, at 2.146 billion yuan, 2.008 billion yuan, and 1.680 billion yuan, respectively

NJTC

JSST

Keli

Overview of A-share Stock Buybacks: Today, 4 Companies Disclosed Buyback Progress

EAST-ASIA PHARMACEUTICAL's wholly-owned subsidiary Hangzhou Shanli Biomedical Technology Co., Ltd. has obtained the CNAS laboratory accreditation certificate, which is valid from May 20, 2025, to May 19, 2031. This accreditation enhances the laboratory's management and technical capabilities, improves the company's product quality and R&D capabilities, and promotes high-quality development, but has no significant impact on the company's current performance

EAST-ASIA PHARMACEUTICAL: Subsidiary obtains CNAS laboratory accreditation certificate

EAST-ASIA PHARMACEUTICAL recently obtained the drug registration certificate for Levofloxacin Tablets approved by the National Medical Products Administration. This drug is used to treat various infections. Several domestic manufacturers have already obtained registration certificates, and the national sales are expected to be approximately 435 million yuan in 2024. This certificate will positively impact the company's future development

EAST-ASIA PHARMACEUTICAL: Levofloxacin Tablets Approved for Drug Registration Certificate

EAST-ASIA PHARMACEUTICAL announced that its active pharmaceutical ingredient, Trimebutine, has obtained the registration certificate from the Korean Food and Drug Administration. This medication can be used to treat various symptoms of gastrointestinal motility disorders. It is expected that the national sales of Trimebutine maleate formulations will reach 372 million yuan in 2024. This registration certificate will help the company expand into the Korean market and promote its sales in other overseas markets

EAST-ASIA PHARMACEUTICAL: Quetiapine raw materials have obtained the raw material drug registration certificate in South Korea

According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL released its first-quarter report for 2025. The company's first-quarter operating revenue was 191 million yuan, a year-on-year decrease of 45.85%; the net loss attributable to shareholders of the listed company was 6.9196 million yuan, turning from profit to loss; the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 10.5059 million yuan, turning from profit to loss; the basic loss per share was 0.06 yuan/share

EAST-ASIA PHARMACEUTICAL released its first-quarter performance, reporting a net loss attributable to the parent company of 6.9196 million yuan, turning from profit to loss

According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL announced that its wholly-owned subsidiary, Zhejiang Dongbang Pharmaceutical Co., Ltd., has recently received the active pharmaceutical ingredient registration certificate from the Korean Ministry of Food and Drug Safety (Korean MFDS). The product name is Cefotaxime Probenecid, which is a third-generation cephalosporin antibiotic used to treat infections of the respiratory tract, urinary system, biliary tract, and skin soft tissues caused by sensitive bacteria

EAST-ASIA PHARMACEUTICAL: The raw material drug Cefotiam has obtained the raw material drug registration certificate in South Korea

EAST-ASIA PHARMACEUTICAL announced an investment of 60 million yuan to establish a wholly-owned subsidiary, Zhejiang Shan Heng Pharmaceutical Co., Ltd., in Zhejiang Province, aiming to enhance industrial layout and competitiveness. Zhejiang Shan Heng has completed business registration and obtained a business license. This move will enrich the product pipeline, promote business expansion, and align with the company's long-term development strategy and shareholder interests

EAST-ASIA PHARMACEUTICAL invests 60 million yuan to establish a wholly-owned subsidiary Zhejiang Shan Heng

EAST-ASIA PHARMACEUTICAL announced that its Luliconazole active pharmaceutical ingredient has obtained the registration certificate from the Korea Food and Drug Administration. This certification marks the product's eligibility for entry into the South Korean market, which will positively impact the company's expansion in the pharmaceutical market in South Korea and promote the sales of Luliconazole in other overseas markets

YIXINTANG

GUOLIAN AQUATIC

GUOQUAN

GUANGDONG GUANGHONG HOLDINGS

Jointown

Bio-S

Ligao Foods

EAST-ASIA PHARMACEUTICAL: Lu Li Kang Zuo raw materials have obtained the raw material drug registration certificate in South Korea

EAST-ASIA PHARMACEUTICAL(605177.SH)